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I571 ABSTRACT 
The improved hemodialysis system utilizes a second 
polymeric membrane having dialyzate in contact with 
one surface and a urea decomposition solution in 
contact with the other surface. The membrane selec- 
tively passes urea from the dialyzate into the decompo- 
sition solution, while preventing passage of positively 
charged metal ions from the dialyzate into the solution 
and ammonium ions from the solution into the dialy- 
zate. 
19 Claims, 4 Drawing Figurea 
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DIALYSIS SYSTEM 
ORIGIN OF THE INVENTION 
The invention described herein was made in the per- 
formance of work under a NASA contract and is sub- 
ject to the provisions of Section 305 of the National 
Aeronautics and Space Act of 1958, Public Law 83-568 
(72 Stat. 435; 42 USC 2457). 
BACKGROUND OF THE INVENTION 
2 
body fluid. Three major methods of urea removal from 
dialysate have been reported. 
The fvst procedure utilizes an activated carbon bed 
which removes urea by absorption. However, the dem- 
5 onstrated capacity for urea is only 0.2-0.8 grams per 100 
grams of carbon. In another method urea is reduced by 
enzymatic hydrolysis either inside microcapsules or by 
the combination with other absorbents. However, enzy- 
matic decomposition of urea produces large concentra- 
10 tions of ammonium ion which is toxic. Therefore, it is 
essential to achieve rapidly removal of the ammonium 
1. Field of the Invention ion or it can accumulate in the dialyzate and enter the 
nium phosphate to remove the ammonia produced by 
15 enzymatic decomposition of urea in the presence of 
2. Description of the Prior Art urease. Though this system does remove urea from 
A sizable fraction of the estimated 50,000 people who dialyzate it also removes essential metal ions such as 
die of kidney failure each year in the United States are strontium and calcium which must be replaced. Fur- 
free of other complications and might be restored to thermore, large Of zirconium phosphate are 
useful life if their kidney function could be provided 20 required and the process is expensive since the spent 
alysis) and clinical procedures have been developed to 
hemodialysis is practical in many cases. The improved hemodialysis system in accordance 
number of patients who can be treated with a given with the invention obviates the need for an ammonia absorbent in the urea decomposition solution. The sys- kidney machine and the considerable expense of main- tem of the invention permits purification and recircula- taining and staffing a kidney-treatment center. Obvi- tion of dialyzate fluid in an efficient manner and sub- 
ously, a desirable solution lies in the development of an 30 stantially reduces the quantity of dialyzate needed for 
artificial kidney which is inexpensive, portable and ca- dialysis making it feasible to produce a portable, or pable of being operated outside the confines of a hospi- wearable artificial Edney system. The degradation tal with a minimum of medical attention. Attainment of products produced by the dialyzate treating portion of 
this solution will require increased efficiency of mass the apparatus forms a soluble toxic component and a 
transfer and further optimization in design of artificial- 35 soluble nontoxic component. ne toxic component is 
kidney systems. retained in the treating section of the apparatus while 
In recent years, considerable attention has been fo- the nontoxic component may migrate or diffuse back 
cused on methods of reducing the size of the artificial into the dialyzate for elimination in the body of the 
kidney. This requires miniaturization of the membrane- patient. ne system of the invention also prevents diffu- 
containing dialyzer and a significant reduction in the 40 sion of essential metal ions from dialyzate into the treat- 
volume of dialyzing fluid. It is generally conceded that ing solution. 
the toxin primarily responsible for the uremic syndrome Urea is continuously removed from dialyzate in ac- 
has not yet been identified. Even though urea is not cordance with the invention by passing the urea in 
considered particularly toxic, its removal is one of the contact with a polymeric membrane selectively perme- 
chief objectives of dialysis as practiced today. The rea- 45 able to urea. n e  urea passes through the membrane 
son for the concentration on urea removal is that, in the into a solution containing a urea decomposition agent 
absence of more specific knowledge, dialysis based on such as the enzyme urease. The urea is decomposed into 
this principle is obviously beneficial. At least two expla- ammonium and bicarbonate ions. The membrane is 
nations suggest themselves: (a) Unidentified toxicants selectively impermeable to ammonium ion but may pass 
are removed along with the urea. (b) Urea Produces 50 the bicarbonate back into dialyzate and eventually 
toxic products. through the primary membrane into the blood. How- 
In order to increase the efficiency of hemodialysis, it ever, bicarbonate is nontoxic and is readily decomposed 
is desirable to maintain the trans-membrane concentra- and eliminated by exhalation as carbon dioxide. The 
tion gradient of waste metabolites as high as possible. membrane used in the dialyzate purification section is 
Low waste concentrations in the dialyzing fluid have in 55 also selectively nonpermeable to essential positive cati- 
the past been maintained by two methods. The more ons such as strontium and calcium which remain in the 
widely used method is the continual dilution of the dialyzate obviating the need to replenish these metals as 
dialyzed substances in a large reservoir of fluid, usually is practiced in commercial systems. Preferred mem- 
100 to 300 liters. A second method of maintaining the branes are positively charged membranes, suitably poly- 
gradient is to use the dialyzing fluid in a single-pass 60 quaternary substituted cation exchange resins, since 
operation, where the waste-bearing effluent is dis- such membranes do not require gradient effects for 
carded. Even then, more than 100 liters of fluid are providing the desired nonselectivity to passage of cati- 
required. The current research trend in obtaining low ons in either direction. 
concentrations of wastes is to remove them selectively The dialyzate treating apparatus of the invention has 
from the dialyzing fluid. Such an approach would allow 65 demonstrated the capability of removing almost half the 
the use of much smaller volumes of dialyzing fluid. urea content of test dialyzates in 20 hours while retain- 
Among all waste products, urea is by far the major ing UP to about 90% ammonium ions in the treating 
waste metabolite which must be removed daily from the chamber. Operation is continuous and regeneration 
The present invention relates to a hemodialysis sys- blood. A commercial apparatus Utilizes sodium zirco- 
tem and, more particularly, to an improved system for 
selectively removing urea from dialyzate. 
artificially. At present, artificial kidneys (using hemodi- 
the point where long-term sustenance of life by periodic 
zirconium phosphate absorbent is not and 
must be discarded* 
SUMMARY OF THE INVENTION . 
The limitations in using hemodialysis are the small 25 
3 
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simply involves replacing the low cost urease enzyme. 
The system substantially reduces the amount of dialy- 
zate required and a small size is indicated for use in 
current clinical dialyzers in a typical thrice weekly 
dialysis regimen. 
These and many other features and attendant advan- 
tages of the invention will become apparent as the in- 
vention becomes better understood by reference to the 
following detailed description when considered in con- 
junction with the accompanying drawings. 
BRIEF DESCRIPTION OF THE DRAWINGS 
FIG. 1 is a schematic illustration of a spent dialyzate 
urea removal unit in accordance with the invention; 
FIG. 2 is a schematic illustration of an artificial kid- 
ney hemodialysis unit incorporating the dialyzate treat- 
ing unit of the invention; 
FIG. 3 is a schematic illustration of a hollow fiber 
hemodialysis apparatus in accordance with the inven- 
tion; and 
FIG. 4 is a schematic illustration of an artificial kid- 
ney machine incorporating a single cationic membrane 
and having the urease present in the dialyzate. 
DESCRIPTION OF THE PREFERRED 
EMBODIMENTS 
Referring now to FIG. 1 the dialyzate treating unit 10 
of the invention includes a container 12 divided into a 
dialyzate chamber 14 and a urea decomposition cham- 
ber 16 by a common membrane 18. Spent dialyzate 
enters chamber 14 through inlet 20 and purified dialy- 
zate leaves through outlet 22. The membrane 18 is per- 
meable to the urea which diffuses into chamber 16 
which contains a solution of urease enzyme. The en- 
zyme decomposes the urea into ammonium ion which is 
repelled by the membrane 18 and is retained in chamber 
14 and into bicarbonate which may permeate through 
the membrane 18 into the dialyzate. The purified dialy- 
zate may be recycled to the dialysis section of a hemodi- 
alysis unit. 
The membrane 18 is formed of a high molecular 
weight synthetic polymer having good tensile strength, 
elongation and flexural strength. The membrane is se- 
lectively permeable to solvated urea molecules while 
preventing passage of larger molecules and preventing 
passage of cationic ammonium or metallic ions in either 
direction. Preferred membrane materials are synthetic 
polymers containing cationic groups such as phospho- 
nium, sulfonium or quaternary nitrogen. A suitable 
membrane material is RAI P-4025 which is a polyethyl- 
ene containing 45% grafted vinylpyridine having an 
ion-exchange capacity of 5 meq/gm and a resistance of 
1 ohm-cm2. The membrane may be utilized in various 
thicknesses depending on the desired flow rate and 
mechanical properties required in the purification unit. 
The thickness may be from 1-15 mil, generally around 
2-10 mil in thickness. The surface area membrane is 
selected so as to give adequate removal of urea from the 
dialyzate. From experiments to date, it is estimated that 
the surface required would be about 10 to 40 square 
inches. 
The treating chamber 16 should contain concentra- 
tions of low molecular weight ingredients equal to that 
contained in the dialyzate chamber 14. For example, 
buffer concentration should be equivalent as should 
d i n e  concentration to prevent diffusion from dialyzate 
into the treating solution. The urease concentration 
should be sufficient to significantly decrease the amount 
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of urea in the dialyzate. Usually the urea concentration 
should be at least 25-300% the concentration of the 
urea in the dialyzate in order to provide adequate peri- 
ods before the need to recharge urease to the treating 
chamber. 
The dialyzate treating unit of the invention can be 
combined with many diverse types of hemodialysis 
units. In its simplest form shown in FIG. 2 the dialyzate 
chamber 24 would have one wall formed by the pri- 
mary membrane 26 and another wall portion formed of 
the secondary treating membrane 28. Blood from an 
artery enters the inlet 30 to continuous flow through 
chamber 32 and leaves through outlet 34. As the blood 
flows past primary membrane 26 such as a cellulose 
ester, preferably a cupprammonium treated cellulose 
acetate, urea diffuses through membrane 26 into the 
dialyzate chamber 24. The urea in turn will dfluse 
through secondary positively charged membrane 28 
into the treating section 36 where it will be decomposed 
by urease into ammonium and bicarbonate ions. The 
bicarbonate ions will build up in concentration and can 
flow backwards through membrane 28 into the dialy- 
zate and in turn through membrane 26 into the blood. 
The blood will leave through outlet 34 and will be 
returned to a vein of the subject by intravenous injec- 
tion. 
In the typical artificial kidney machine a very thin 
film of flowing blood is separated from the surrounding 
dialyzate solution by an approximately 3 mil thick semi- 
permeable cellulose acetate membrane. This membrane 
allows substances in normal molecular solution and the 
solvent to pass through its pores but it prevents the 
passage of very large molecules such as proteins and 
cellular constituents of the blood. The membrane does 
not permit the passage of bacteria and viruses so that 
sterilization of the apparatus located outside the mem- 
brane is not required. Since the apparatus operates by 
diffusion and osmosis the dialyzate liquid must contain 
physiological concentrations of all membrane-passing, 
dissolved normal constituents of the blood, electrolytes 
in particular, which are required to be maintained in the 
blood. The dialyzate may also contain high concentra- 
tions of substances which it is desired to introduce into 
the blood stream by diffusion such as drugs, dextrose, 
etc. The dialyzate must be at the same temperature as 
the blood this usually being effected by thermostatic 
control. Oxygen may be bubbled into the dialyzate so as 
to maintain the oxygen content of blood in a normal 
condition. The kidney machine may also contain a 
pump and means to introduce anticoagulants such as 
hirudin or heparin into the blood to prevent clotting of 
the blood on all surfaces of the apparatus that are in 
contact with blood. 
A principle requirement of a kidney machine is that 
the semipermeable membrane should have a large sur- 
face area to insure adequate osmotic interchange be- 
tween the blood and the dialyzate. This usually requires 
that the blood flow in a very thin film to provide maxi- 
mum contact with the membrane bathed by the dialy- 
zate liquid. Many configurations of kidney machines 
have been devised and are all compatible with the dialy- 
zate treating section or unit of the invention. The blood 
dialyzate portion of the equipment may be in the form 
of a rotary drum apparatus in which a blood-filled flat 
cellophane tube is wound in helical fashion around a 
rotating drum made of wire mesh, the drum being 
bathed or submerged in dialyzate. A sandwich-type 
apparatus has been devised and can more readily be 
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utilized for ultrafiltration under pressure. In this form of 
construction a flat cellophane bag is sandwiched be- 
tween grooved plates of plastic. The dialyzate liquid 
flows through the grooves in the opposite direction to 
the flow of blood in the cellophane bag. However, this 
configuration provides dead flow spaces providing an 
inherent danger of clotting unless large amounts of 
anticoagulants are used. Another configuration is a 
twin-coil apparatus in which the semipermeable mem- 
brane is in the form of a flat, wide cellophane tube 
which is coiled in two tiers around the hollow core. The 
coils are mounted inside a container through which the 
rinsing liquid is passed. A very thin film of blood flows 
through the coils which present a large area of contact 
with the surrounding liquid. This has the advantage that 
the modules can be supplied, sterilized and ready to use 
inside the container and can be quickly and easily ex- 
changed. 
Hollow fibers also offer the advantage of high surface 
area in a very compact volume. Hollow fibers may be 
utilized for either or both of the membranes discussed 
herein. A more complete artificial kidney machine em- 
ploying hollow fibers is illustrated in FIG. 3. In the 
kidney machine 40 of FIG. 3 a cylindrical container 42 
houses the dialyzate chamber 44. The container 42 is 
surrounded with a heating jacket 46 such as an electric 
resistance heater powered by thermostatically con- 
trolled power unit 48. The cellulose acetate membrane 
is in the form of a plurality of fine filamentary hollow 
fibers 50 having their inlet ends potted to a common 
inlet header 52 and their outlet ends connected to a 
common outlet header 54. Each of the headers 52 and 
54 can be threadingly and sealingly received into the 
side walls 56, 58 of the container 42. 
The second membrane may also be in the form of a 
plurality of hollow fiber tubes containing the urease 
solution and connected to the common inlet and outlet 
headers as in the blood chamber described above. How- 
ever, since there is no need to recirculate the urease 
solution the dialyzate treating chamber can be in the 
form of a cartridge 60 in which the plurality of hollow 
fibers 62 have both ends connected to a base 62 which 
is threadingly received into a wall 58 of the container 
42. A further replaceable cartridge element 64 may be 
provided in the chamber containing an effective absor- 
bent such as activated carbon to remove other impuri- 
ties from the dialyzate. 
The kidney machine 40 of FIG. 3 is utilized by filling 
the chamber 44 with dialyzate through inlet plug 66. 
The absorbent cartridge 64, dialyzate treating cartridge 
60 and blood cartridge 68 are inserted. The heater 48 is 
turned on and a first catheter 70 is inserted into a vein of 
the subject and connected to blood outlet 72 and a sec- 
ond catheter 74 is inserted into an artery of the subject 
and connected to the pump 76. The pump is then ener- 
gized and as blood is drawn from the artery and 
through the hollow fiber tubes 50 of the blood car- 
tridge, urea passes into the common body of dialyzate 
44 and then through the walls of hollow fiber tubes 62 
of the cartridge 60 where urea is decomposed and re- 
tained therein. However, the positively charged walls 
of the hollow fibers 62 prevent the ammonium ions 
from entering the dialyzate and prevent metal cations 
from the dialyzate from entering the tubes 62. Other 
impurities are absorbed onto the granules 78 of acti- 
vated carbon within the cartridge 64. As the urease 
containing cartridge 60 is exhausted a new cartridge is 
inserted. Similarly, the activated carbon cartridge 64 
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can be replaced as needed. Should the hollow fibers of 
the blood cartridge 68 become damaged or worn out, 
that unit can be replaced. Any of the cartridges can be 
readily removed for sterilization. 
An example of practice follows. 
Two cylindrical chambers of about 30 mls. capacity 
were separated by a positively charged membrane (RAI 
P-4025 membrane) having a surface area of about one 
square inch. Synthetic test solutions were introduced on 
each side of the membrane. The synthetic dialyzate 
contained about 2 gmfliter of urea, 4.5 gmAiter of SO- 
dium acetate trihydrate and 5.8 gmfliter of sodium 
chloride. The urease chamber test solution contained 
about 1 gmfliter of urease, 4.5 gmfliter sodium acetate 
trihydrate and 5.8 gmfliter of sodium chloride. 
After six hours analysis showed that the quantity of 
urea in dialyzate had dropped about 25% and that sig- 
nificant concentrations of ammonium were present in 
the urease chamber. After 20 hours, urea concentration 
had dropped 45% and about 90% of the ammonia was 
present in the urease chamber, but the urease chamber 
now is found to contain no urea. 
The above experiment demonstrates that urea readily 
diffuses through the membrane and is rapidly hydro- 
lyzed to ammonium bicarbonate. The initial rate of 
removal of urea from dialyzate was about 0.1 g m h r  
and about 0.05 gm/hr after 20 hours for the 4-5 mil 
thick film utilized. Higher diffusion rates can be ex- 
pected with thinner membranes. The positively charged 
membrane also demonstrated the ability to isolate the 
toxic ammonium ion from the dialyzate and to retain the 
essential metal cations within the dialyzate. Preliminary 
estimates indicate that the dialyzate membrane need 
only require 24 in20f surface area to be compatible with 
the urea production of conventional hemodialysis units. 
A cartridge or treating chamber could readily be 
housed in a 1 ft. X 2 in. X 2 in. unit which is well within 
design constraints for continuous operation in portable 
or wearable artificial kidney apparatus for a typical 
thrice weekly dialysis regimen. Urease enzyme is not 
expensive and can readily be recharged for the next 
dialysis treatment. 
The urease solution could be pumped past the mem- 
brane and removed from the chamber for continuous 
replenishment of urease and removal of ammonium 
ions. Similarly the dialyzate could be continuously 
pumped in concurrent or countercurrent flow past both 
membranes to increase urea transfer rate from the blood 
into the dialyzate. Another configuration would be to 
encapsulate the urease within a positively charged poly- 
meric membrane and place the capsules in-line in the 
dialyzate flow path to absorb urea from the dialyzate 
while retaining ammonium salts within the capsules. 
The cationic polymer membrane can also be utilized 
to form a single membrane, low dialyzate volume arti- 
ficial kidney machine. Referring now to FIG. 4, the 
machine 70 includes a container 72 divided into a blood 
chamber 74 and a dialyzate chamber 76 by means of a 
cationic membrane 78. The membrane 78 repels and 
prevents passage of NH4+ ions 80 and M+ ions 82. 
Therefore the dialyzate need not contain equilibrium 
concentrations of the essential cations such as strontium 
or calcium. 
The blood chamber 74 contains an inlet 84 and an 
outlet 86. As the blood flows past the membrane 78, 
essential large proteins, cellular constituents and cations 
are retained in the blood, while urea 88 traverses the 
membrane 78, enters the dialyzate chamber 76 and is 
4,094,775 
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decomposed into NH4+ and HC03-. The ammonium 10. A method of selectively removing urea from an 
ion is retained in the dialyzate chamber. Substantially aqueous liquid containing urea and positive metal Cati- 
smaller amounts of dialyzate are required compared to ons comprising the steps of: 
dilution and continuous flowing dialyzate configura- placing the liquid in contact with a first surface of a 
tions. 5 cationically charged polymeric membrane selec- 
It is to be realized that only preferred embodiments of tively permeable to urea and having low permea- 
the invention have been described and that numerous bility to cations; 
substitutions, modifications and alterations are permissi- placing an urea decomposition Solution containing an 
ble without departing from the spirit and scope of the urea decomposition agent in contact with a second 
invention as defined in the following claims. surface of the membrane; and 
selectively permeating urea from the liquid through 
the membrane into the solution thereby decompos- 
ing urea into ammonium cations and bicarbonate 
whereby the ammonium cations are retained in the 
decomposition solution and the metal cations are 
retained in the liquid. 
11. A method according to claim 10 in which the 
12. A method according to claim 11 in which the 
10 
What is claimed is: 
1. A system for selectively removing urea from an 
aqueous liquid containing urea and positive metal cati- 
ons comprising in combination: 
a container divided into a first chamber and a second 15 
chamber by means of a continuous sheet of cationi- 
cally charged polymeric membrane selectively 
cations; 
liquid; and meq/gm. 
said second chamber receiving a solution containing a 
urea decomposition agent whereby said cations are 
repelled by said membrane and retained in said 25 
liquid and urea permeates through the membrane 
into the solution and is decomposed into bicarbon- 
ate and ammoniumy the ammonium being retained 
in the solution in the second chamber. 
brane contains quaternary ammonium groups. 
brane is a vinyl pyridine grafted polyethylene. 
4. A system according to claim 1 in which the mem- 
brane has a thickness from 1 to 15 mils. 
5. A system according to claim 4 in which the mem- 
brane has an exchange capacity of 1 to 20 meq/gm. 
6. A system according to claim 1 in which the first 
chamber is a hollow body having said membrane as one 
wdl thereof and having an inlet and outlet for flowing 40 
said liquid past a first surface of the membrane. 
7. A system according to claim 1 in which the urea 
decomposition agent is urease. 
8. A system according to claim 7 in which the urease 
concentration of the solution is at least 25% by weight 45 
of the urea content of the liquid. 
9. A system according to claim 7 in which the liquid 
is dialyzate containing urea and further including a 
blood dialysis membrane selectively permeable to urea 
having one surface in contact with said dialyzate and a 50 and chamber. 
permeable to urea and having low permeability to membrane contains quaternary ammonium groups* 
said first chamber including means for receiving said 2o membrane has an exchange capacity Of from to 2o 
13. A method according to claim 12 in which the 
membrane is a vinyl pyridine grafted polyethylene hav- 
ing a thickness from 1 to 15 mils. 
14. A method according to claim 11 in which the 
agent is urease. 
15. A method according to claim 14 in which the 
urease concentration of the decomposition solution is at 
least 25% of the concentration of urea in the urea con- 
16. A method according to claim 14 in which the urea 
17. A method according to claim 14 in which the urea 
18. An artificial kidney machine comprising in combi- 
enclosure means having an inlet and an outlet, and 
having a wall surface formed of a cationically 
charged membrane defining a channel for flowing 
urea containing blood past one surface ofthe mem- 
brane; 
urea removal means comprising walls defining a 
chamber, said chamber including a solution of ure- 
ase having a concentration at least 25% by weight 
of the urea content of the blood; and 
means for supplying the urea permeate from the sec- 
ond surface of the membrane to the urease solution. 
19. A machine according to claim 18 in which the 
membrane forms a common wall portion of said channel 
2. A system according to claim 1 in which the mem- 3o taining liquid. 
3. A system according to claim 2 in which the mem- containing liquid is dialyzate from a blood dialysis unit. 
containing liquid is blood, 
nation: 
35 
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